The study, led by Cesar Camilo Calderon Torres and Yang Guo of Hebei Medical University together with Jiashuo Huang and Jie Chang of Capital Medical University, drew on the China Health and Retirement Longitudinal Study, one of the country’s most important population health surveys. The team followed 6,298 postmenopausal women across survey waves from 2011 to 2018, tracking whether and when they developed combinations of hypertension, diabetes, and dyslipidemia, the three metabolic conditions that together drive much of the global burden of cardiovascular disease. Metabolic multimorbidity was defined as the co-occurrence of two or more of these disorders, a state that is far more dangerous than any single condition alone because the diseases amplify one another’s effects on the heart, kidneys, and brain.

To measure the relationship between menopause timing and disease risk, the researchers categorized self-reported age at menopause into three groups: early menopause before age 45, normal menopause between 45 and 55, and late menopause after 55. They then applied Cox proportional hazards models, a statistical technique that estimates how a given exposure changes the rate at which an event occurs over time, adjusting for a battery of sociodemographic and lifestyle factors including education, residence, body mass index, and health behaviors. This adjustment is critical in observational research, because women with different menopause timing may also differ in weight, smoking habits, socioeconomic status, and access to healthcare, any of which could confound the apparent relationship.

The results were unambiguous for late menopause. Over 12,632 person-years of follow-up, 583 women developed metabolic multimorbidity, and those who experienced menopause after age 55 had a 48 percent higher risk of doing so compared with women whose menopause fell in the normal window. The adjusted hazard ratio of 1.48, with a 95 percent confidence interval of 1.08 to 2.02, indicates a statistically robust association. Perhaps even more telling was the dose-response analysis: each additional year of age at menopause was associated with a 2 percent increase in multimorbidity risk. Restricted cubic spline analyses, which model the shape of the relationship between exposure and outcome without forcing it into a straight line, supported a pattern in which risk climbs steadily with later menopause timing.

When the researchers broke the outcome down into its individual components, the picture became more nuanced. Late menopause was most strongly linked to diabetes, with a hazard ratio of 1.49, meaning women with late menopause had roughly a 49 percent higher risk of developing the disease. Hypertension showed a more modest but still detectable linear increase, with each additional year of menopause age raising risk by about 1 percent. Dyslipidemia, by contrast, showed no significant association with menopause timing. This pattern is biologically plausible: prolonged ovarian estrogen production influences fat distribution, insulin sensitivity, and glucose metabolism, and extended exposure may promote the gradual accumulation of visceral adiposity and insulin resistance that culminates in type 2 diabetes.

What makes the finding counterintuitive is the long-standing assumption that later menopause is cardioprotective. Estrogen is known to exert favorable effects on lipid profiles and vascular function during reproductive years, and early surgical or natural menopause has repeatedly been tied to elevated cardiovascular risk. The new study did not contradict that literature entirely, because early menopause showed no significant association with metabolic multimorbidity in this cohort, with a hazard ratio of 0.93 that crossed the line of statistical significance. Instead, the data suggest a more complex curve in which both ends of the menopause timing spectrum may carry different types of risk, with late menopause favoring metabolic disease and early menopause potentially favoring other cardiovascular outcomes that this study did not measure.

The authors also examined whether the association varied across subgroups defined by educational level or urban versus rural residence, and found no significant interactions. That consistency matters for public health planning in China, where the population is aging rapidly and metabolic diseases are rising in both cities and the countryside. If the relationship between late menopause and metabolic multimorbidity holds across social strata, then menopause timing could serve as a simple, zero-cost marker that clinicians can record during routine history-taking to identify women who warrant closer metabolic surveillance in later life.

Several caveats deserve attention. Age at menopause was self-reported, and recall error is a known limitation in retrospective studies of reproductive history, particularly among older women surveyed years after the event. The CHARLS cohort is community-dwelling and middle-aged to older, so the findings may not generalize to women who died before recruitment or who experienced very early surgical menopause. Observational designs also cannot rule out residual confounding by factors such as parity, breastfeeding history, oral contraceptive use, or hormone therapy, none of which can be fully captured in a general aging survey. And because the outcome was incident multimorbidity during a relatively short follow-up window, longer studies will be needed to confirm whether the association persists and strengthens with age.

Even with those limitations, the study offers a valuable reframing of menopause as a metabolic event, not merely a reproductive one. The menopausal transition is increasingly recognized as a window of heightened vulnerability, when shifts in estrogen, body composition, and sleep converge to accelerate cardiometabolic risk. By showing that the timing of that transition predicts the likelihood of accumulating multiple metabolic diseases simultaneously, the researchers provide a concrete signal that preventive strategies, including glucose screening, blood pressure monitoring, and lifestyle counseling, could be tailored to menopause history. For the millions of women worldwide who experience late natural menopause, the message is not alarm but awareness: a longer reproductive lifespan may carry a metabolic bill that arrives later in life, and knowing that in advance is the first step toward paying it down early.

Subject of Research: The association between age at menopause and metabolic multimorbidity risk in Chinese postmenopausal women

Article Title: Age at menopause and major metabolic disorders among Chinese middle-aged and older women

Article References: Age at menopause and major metabolic disorders among Chinese middle-aged and older women. (n.d.). https://doi.org/10.1186/s12916-026-05225-9

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05225-9

Keywords: menopause, metabolic multimorbidity, diabetes, hypertension, dyslipidemia, women's health, China, CHARLS, estrogen exposure, aging, epidemiology, Cox proportional hazards

The emphasis of the research is on epigenetic aging, which pertains to the biological age of an individual as determined by changes in DNA methylation. DNA methylation is a chemical modification of DNA that plays a significant role in gene regulation and expression. As individuals age, the patterns of methylation change, which can reflect the overall health and aging process within the body. This study found that women with heightened biological age as indicated by their DNA methylation profiles had an increased likelihood of developing breast cancer, suggesting a direct connection between accelerated epigenetic aging and cancer risk.

The subject of this investigation specifically focuses on postmenopausal, non-Hispanic white women, a demographic known to face elevated breast cancer risks especially after menopause. The researchers conducted a detailed analysis of blood samples and discovered a stark correlation: women whose biological markers indicated they were aging more rapidly were statistically more likely to be diagnosed with breast cancer. Intriguingly, this risk was amplified in women who had undergone bilateral oophorectomy before natural menopause, an operation that results in a significant reduction of estrogen levels – a hormone integral to maintaining both breast health and overall physiological processes.

Understanding how estrogen plays a role in both aging and cancer susceptibility is critical. The study suggests that diminished lifetime estrogen exposure directly contributes to the acceleration of aging markers in women, thereby influencing their vulnerability to breast cancer. This finding is particularly relevant for health practitioners and researchers as it underlines the need for tailored approaches in assessing cancer risks in different populations of women, particularly those with varied reproductive histories.

Furthermore, the findings extend beyond biological demographics, as lifestyle factors significantly impact both epigenetic aging and breast cancer susceptibility. The research indicates that obesity is linked to accelerated biological aging, thereby further heightening the cancer risk in obese women. Conversely, the effects of hormone replacement therapy varied depending on the regimen’s type and duration, illustrating the complex relationship between hormonal interventions and cancer risk.

One of the key takeaways from this research is the potential for early detection, which remains a cornerstone of effective breast cancer treatment. The current framework for assessing breast cancer risk often includes conventional factors such as age, family history, and lifestyle habits; however, these determinants may not provide a comprehensive overview of an individual’s actual risk. By integrating a blood test that measures biological aging into the risk assessment protocol, clinicians may better identify high-risk individuals and develop personalized prevention strategies.

As the study points out, utilizing this blood test for routine health screenings for women could revolutionize how healthcare providers approach breast cancer detection. The practical implications are profound, providing women with actionable insights into their health that can empower them to take proactive steps in mitigating risk through healthy lifestyle changes. Enhancing awareness around epigenetic aging could lead to more effective health campaigns promoting balanced diets, regular physical activity, and medically supervised hormone therapies.

Although the findings present promising advancements in breast cancer risk assessment, the authors caution that additional studies are imperative. There remains a need for validation of these findings in broader and more diverse populations to establish the universal applicability of this blood test approach. However, this innovative research offers a non-invasive, cost-effective strategy to predict breast cancer risks, highlighting the intricate connections between genetic health, environmental influences, and disease susceptibility.

In summary, the study advances an intriguing narrative on the importance of biological aging in understanding breast cancer risk, particularly among older women. The exploration of DNA methylation and its implications for epigenetic aging provides new avenues for future research and potential applications in routine medical practice. There lies a collective responsibility among researchers, clinicians, and public health advocates to glean insights from these findings, aiming to enhance breast cancer prevention strategies that could ultimately save lives.

With the continued research into the applications of epigenetic markers in cancer risk evaluation, healthcare may witness a transformative approach to managing breast cancer, leading to safer, more informed health practices for women worldwide.

Subject of Research:
Article Title: DNA-methylation age and accelerated epigenetic aging in blood as a tumor marker for predicting breast cancer susceptibility
News Publication Date: January 21, 2025
Web References:
References:
Image Credits: © 2024 Jung et al.

Keywords: aging, DNA methylation-based marker of aging, pre-diagnostic DNA, breast cancer, tumorigenesis, postmenopausal women